private:carsgen
|
10048828
|
Nov 18th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 18th, 2019 03:57PM
|
Nov 18th, 2019 03:57PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 17th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 17th, 2019 04:22PM
|
Nov 17th, 2019 04:22PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 16th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 16th, 2019 04:17PM
|
Nov 16th, 2019 04:17PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 15th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 15th, 2019 12:53PM
|
Nov 15th, 2019 12:53PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 13th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 13th, 2019 01:18PM
|
Nov 13th, 2019 01:18PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 12th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 12th, 2019 03:00PM
|
Nov 12th, 2019 03:00PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 11th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 11th, 2019 02:58PM
|
Nov 11th, 2019 02:58PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 10th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 10th, 2019 06:05PM
|
Nov 10th, 2019 06:05PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 9th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 9th, 2019 05:32PM
|
Nov 9th, 2019 05:32PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|
private:carsgen
|
10048828
|
Nov 8th, 2019 12:00AM
|
CARsgen Therapeutics
|
1.1K
|
27.00
|
Open
|
Biotechnology
|
Nov 8th, 2019 02:43PM
|
Nov 8th, 2019 02:43PM
|
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma.
CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide.
|
Open
|
Immunotherapy, solid tumor, CAR-T, oncology
|
Open
|
1F, Building 2, No.466, Yindu Rd
|
Shanghai
|
Shanghai
|
CN
|
200231
|
|
CARsgen Therapeutics
|
|
|